Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2017 shares
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Entity Registrant Name	Akari Therapeutics Plc
Entity Central Index Key	0001541157
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	AKTX
Entity Common Stock, Shares Outstanding	1,177,693,393

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 30,118,882	$ 34,098,812
Short-term investments	0	10,021,963
Prepaid expenses and other current assets	1,686,217	1,513,006
Total Current Assets	31,805,099	45,633,781
Restricted cash	142,200	142,168
Property and equipment, net	74,205	58,364
Patent acquisition costs, net	31,837	39,365
Total Assets	32,053,341	45,873,678
Current Liabilities:
Accounts payable	2,842,497	2,214,313
Accrued expenses	1,305,824	1,837,647
Liabilities related to options and warrants	4,995,020	7,662,808
Total Current Liabilities	9,143,341	11,714,768
Other long-term liability	58,036	56,360
Total liabilities	9,201,377	11,771,128
Commitments and Contingencies
Shareholders’ Equity:
Share capital of GBP .01 par value Authorized: 5,000,000,000 ordinary shares; issued and outstanding: 1,177,693,393 at June 30, 2017 and 1,177,693,383 at December 31, 2016	18,340,894	18,340,894
Additional paid-in capital	92,727,034	90,979,363
Accumulated other comprehensive loss	(373,827)	(280,097)
Accumulated deficit	(87,842,137)	(74,937,610)
Total Shareholders’ Equity	22,851,964	34,102,550
Total Liabilities and Shareholders’ Equity	$ 32,053,341	$ 45,873,678

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - £ / shares	Jun. 30, 2017	Dec. 31, 2016
Common stock, par value	£ 0.01	£ 0.01
Common stock, shares authorized	5,000,000,000	5,000,000,000
Common stock, shares issued	1,177,693,393	1,177,693,383
Common stock, shares outstanding	1,177,693,393	1,177,693,383

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Operating Expenses:
Research and development costs	$ 3,782,185	$ 5,443,105	$ 9,784,884	$ 6,942,648
General and administrative expenses	3,566,952	2,076,795	5,847,442	4,429,230
Total Operating Expenses	7,349,137	7,519,900	15,632,326	11,371,878
Loss from Operations	(7,349,137)	(7,519,900)	(15,632,326)	(11,371,878)
Other Income (Expense):
Interest income	38,564	17,307	77,451	48,111
Changes in fair value of option/warrant liabilities	6,999,529	976,452	2,667,788	1,680,787
Foreign currency exchange gains/(losses)	(6,293)	87,210	(13,052)	241,641
Other expenses	(2,679)	(12,447)	(4,388)	(35,423)
Total Other Income (Expense)	7,029,121	1,068,522	2,727,799	1,935,116
Net Loss	(320,016)	(6,451,378)	(12,904,527)	(9,436,762)
Other Comprehensive Loss:
Foreign Currency Translation Adjustment	(48,577)	(155,409)	(93,730)	(348,353)
Comprehensive Loss	$ (368,593)	$ (6,606,787)	$ (12,998,257)	$ (9,785,115)
Loss per common share (basic and diluted)	$ (0.00)	$ (0.01)	$ (0.01)	$ (0.01)
Weighted average common shares (basic and diluted)	1,177,693,383	1,177,693,383	1,177,693,383	1,177,693,383

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY - 6 months ended Jun. 30, 2017 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2016	$ 34,102,550	$ 18,340,894		$ (280,097)	$ (74,937,610)
Balance (in shares) at Dec. 31, 2016		1,177,693,383	90,979,363
Stock-based compensation	1,747,671	$ 0	$ 1,747,671	0	0
Issuance of ordinary shares upon conversion of deferred shares	0	$ 0		0	0
Issuance of ordinary shares upon conversion of deferred shares (in shares)		10	0
Comprehensive Loss	(12,998,257)	$ 0	$ 0	(93,730)	(12,904,527)
Balance at Jun. 30, 2017	$ 22,851,964	$ 18,340,894		$ (373,827)	$ (87,842,137)
Balance (in shares) at Jun. 30, 2017		1,177,693,393	92,727,034

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash Flows from Operating Activities:
Net loss	$ (12,904,527)	$ (9,436,762)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	22,553	18,785
Stock-based compensation	1,747,671	1,622,211
Changes in fair value of the liability for options and warrants	(2,667,788)	(1,680,787)
Foreign currency exchange loss (gains)	13,052	(356,954)
Increase in assets:
Prepaid expenses and other current assets	(172,022)	(852,418)
Increase (decrease) in liabilities:
Accounts payable and accrued expenses	92,205	(2,452,151)
Other liabilities	1,676	6,062
Total adjustments	(962,653)	(3,695,252)
Net Cash Used in Operating Activities	(13,867,180)	(13,132,014)
Cash Flows from Investing Activities:
Purchase of property and equipment	(36,885)	(47,980)
Purchase of short-term investments	0	(46,120,172)
Redemption of short-term investments	10,021,963	0
Net Cash Provided by (Used In) Investing Activities	9,985,078	(46,168,152)
Cash Flows from Financing Activities:
Effect of Exchange Rates on Cash and Cash Equivalents	(97,828)	42,625
Net Decrease in Cash and Cash Equivalents	(3,979,930)	(59,257,541)
Cash and Cash Equivalents, beginning of period	34,098,812	68,919,995
Cash and Cash Equivalents, end of period	$ 30,118,882	$ 9,662,454

Nature of Business

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations [Text Block]

NOTE 1 – Nature of Business

Akari Therapeutics, Plc, (the “Company” or “Akari”), is incorporated in the United Kingdom. The Company is a clinical-stage biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases.

The Company is subject to a number of risks similar to those of clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company’s cost structure. There are no assurances that the Company will be able to obtain additional financing on favorable terms, or at all or successfully market its products.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 2 – Summary of Significant Accounting Policies

Basis of Presentation – The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, including normal and recurring adjustments, which the Company considers necessary for the fair presentation of financial information. The results of operations and comprehensive loss for the three and six months ended June 30, 2017 and June 30, 2016, are not necessarily indicative of expected results for the full fiscal year or any other period.

Principles of Consolidation – The condensed consolidated financial statements include the accounts of the Company and Volution Immuno Pharmaceuticals SA, a private Swiss company, (“Volution”), its wholly-owned subsidiary.

All intercompany transactions have been eliminated.

Foreign Currency – The functional currency of the Company is U.S. dollars as that is the primary economic environment in which the Company operates as well as the currency in which it has been financed.

The reporting currency of the Company is U.S. Dollars. The Company translated its non-U.S. operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive loss. Gains or losses from foreign currency transactions are included in foreign currency exchange gains (losses).

Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities. Management’s estimates and judgments include assumptions used in the evaluation of impairment and useful lives of intangible assets (patents), accrued liabilities, deferred income taxes, liabilities related to stock options and warrants, stock-based compensation and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.

Fair Value Measurements – The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, restricted cash, accounts payable and accrued liabilities approximate fair value due to their short-term maturities.

The Company’s liabilities related to options and warrants relate to equity and debt financing rounds and options related to RPC Pharma Limited (“RPC”), Akari’s majority shareholder, and are recognized on the balance sheet at their fair value, with changes in the fair value accounted for in the Statements of Comprehensive Loss and included in changes in fair value of option/warrant liabilities.

Cash and Cash Equivalents – The Company considers all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no cash equivalents as of June 30, 2017 and December 31, 2016.

Short-term investments – Short-term investments consist of certificates of deposit that are expected to be converted into cash within one year.

Restricted cash – Restricted cash is collateral for a letter of credit related to the Company’s office lease.

Prepaid Expenses and Other Current Assets – Prepaid expenses and other current assets consist principally of VAT receivables and prepaid expenses.

Property and equipment, net – Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:

	Years

Computers, peripheral, and scientific equipment		3
Office furniture and equipment		3

Depreciation expense for the three and six months ended June 30, 2017 and 2016 was $10,952 and $9,418 and $21,044 and $17,257, respectively.

Long-Lived Assets – The Company reviews all long-lived assets for impairment whenever events or circumstances indicate the carrying amount of such assets may not be recoverable. Recoverability of assets to be held or used is measured by comparison of the carrying value of the asset to the future undiscounted net cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment recognized is measured by the amount by which the carrying value of the asset exceeds the discounted future cash flows expected to be generated by the asset.

Patent Acquisition Costs – Patent acquisition costs and related capitalized legal fees are amortized on a straight-line basis over the shorter of the legal or economic life. The estimated useful life is 22 years. The Company expenses costs associated with maintaining and defending patents subsequent to their issuance in the period incurred. Amortization of patent acquisition costs for the three and six months ended June 30, 2017 and 2016 was $762 and $773 and $1,509 and $1,528, respectively.

Accrued Expenses – As part of the process of preparing the Condensed Consolidated Financial Statements, it requires the estimate of accrued expenses. This process involves identifying services that third parties have performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred on these services as of each balance sheet date in the Company’s Condensed Consolidated Financial Statements. Examples of estimated accrued expenses include contract service fees in conjunction with pre-clinical and clinical trials and professional service fees. In connection with these service fees, the Company’s estimates are most affected by its understanding of the status and timing of services provided relative to the actual services incurred by the service providers. In the event that the Company does not identify certain costs that have been incurred or it under or over-estimates the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. The Company makes these judgments based upon the facts and circumstances known to it in accordance with U.S. GAAP.

Research and Development Expenses – Costs associated with research and development are expensed as incurred. Research and development expenses include, among other costs, personnel expenses, costs incurred by outside laboratories, manufacturers’ and other accredited facilities in connection with clinical trials and preclinical studies. Research and development expense for the three and six months ended June 30, 2017 and 2016 was $3,782,185 and $5,443,105 and $9,784,884 and $6,942,648, respectively. The Company accounts for research and development tax credits at the time its realization becomes probable.

Stock-Based Compensation Expense – Stock-based compensation expense is recorded using the fair-value based method for all awards granted. Compensation costs for stock options and awards is recorded in earnings (loss) over the requisite service period based on the fair value of those options and awards. For employees, fair value is estimated at the grant date and for non-employees fair value is re-measured at each reporting date as required by ASC 718, “Compensation-Stock Compensation,” and ASC 505-50, “Equity-Based Payments to Non-Employees.” Fair values of awards granted under the share option plans are estimated using a Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. The Company classifies its stock-based payments as either liability-classified awards or as equity-classified awards. The Company remeasures liability-classified awards to fair value at each balance sheet date until the award is settled. The liability for liability-classified awards generally is equal to the fair value of the award as of the balance sheet date multiplied by the percentage vested at that time. The Company charges (or credits) the change in the liability amount from one balance sheet date to another to changes in fair value of option/warrant liabilities.

Concentration of Credit Risk – Financial instruments that subject the Company to credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents with well-capitalized financial institutions. At times, those amounts may exceed insured limits. The Company has no significant concentrations of credit risk.

Income Taxes – The Company accounts for income taxes in accordance with the accounting rules that require an asset and liability approach to accounting for income taxes based upon the future expected values of the related assets and liabilities. Deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and for tax loss and credit carry forwards, and are measured using the expected tax rates estimated to be in effect when such basis differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will, more likely than not, be realized. The Company has recorded a full valuation allowance on its deferred tax assets as of June 30, 2017 and December 31, 2016.

Uncertain Tax Positions – The Company follows the provisions of ASC 740 “Accounting for Uncertainty in Income Taxes”, which prescribes recognition thresholds that must be met before a tax position is recognized in the financial statements and provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Under ASC 740 “Accounting for Uncertainty in Income Taxes,” an entity may only recognize or continue to recognize tax positions that meet a “more-likely-than-not” threshold. Interest and penalties related to uncertain tax positions are recognized as income tax expense. As of June 30, 2017 and December 31, 2016, the Company had no uncertain tax positions.

Comprehensive Loss – Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company’s other comprehensive loss is comprised of foreign currency translation adjustments.

The following table provides details with respect to changes in accumulated other comprehensive loss, which is comprised of foreign currency translation adjustments, as presented in the balance sheet at June 30, 2017:

Balance January 1, 2017	$	(280,097)

Net current period foreign currency translation loss		(93,730)

Balance June 30, 2017	$	(373,827)

Recent Accounting Pronouncements – In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption of ASU 2014-09 is permitted but not before the original effective date (annual periods beginning after December 15, 2016). When effective, ASU 2014-09 prescribes either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company does not believe the adoption of this standard will have a material impact on its financial position, results of operations or related financial statement disclosures.

In February 2016, the FASB issued ASU No. 2016-02, Leases (ASU 2016-02”). ASU 2016-02 establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its pending adoption of the new standard on the Consolidated Financial Statements.

Fair Value Measurements

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

NOTE 3 – Fair Value Measurements

Fair value of financial instruments:

The estimated fair value of financial instruments has been determined by the Company using available market information and valuation methodologies. Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company could realize in a current market exchange.

The carrying amounts of cash and cash equivalents, short-term investments, restricted cash, accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments.

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820, “Fair Value Measurements and Disclosures” establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1 – quoted prices in active markets for identical assets or liabilities;

Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

	June 30, 2017				December 31, 2016				Fair
	Carrying		Fair		Carrying		Fair		Value
	Amount		Value		Amount		Value		Levels
Liability related to RPC options	$	4,995,020	$	4,995,020	$	7,627,970	$	7,627,970		3
Liability related to warrants		-		-		34,838		34,838		3
	$	4,995,020	$	4,995,020	$	7,662,808	$	7,662,808

In accordance with ASC No. 820, the Company measures its liabilities related to options and warrants on a recurring basis at fair value. The liabilities related to options and warrants are classified within Level 3 fair value hierarchy because the liabilities are based on present value calculations and external valuation models whose inputs include market interest rates, estimated operational capitalization rates, volatilities and illiquidity. Unobservable inputs used in these models are significant.

Upon completion of the acquisition of Volution on September 18, 2015, the Company assumed certain warrants that were issued in connection with several private placements by the Company and certain investors where it sold Ordinary Shares and warrants. Some of the issued warrants contain non-standard anti-dilution terms and accordingly are recorded as liabilities.

	June 30, 2017				December 31, 2016
	Carrying		Fair		Carrying		Fair		Fair
	Amount		Value		Amount		Value		Value
	$		$		$		$		Levels		Reference

Cash and cash equivalents		30,118,882		30,118,882		34,098,812		34,098,812		1		Note 2
Short-term investment		-		-		10,021,963		10,021,963		1		Note 2
Restricted cash		142,200		142,200		142,168		142,168		1		Note 2
Liability related to options and warrants		4,995,020		4,995,020		7,662,808		7,662,808		3		Note 4

Warrants to purchase 5,806,280 Ordinary Shares had full ratchet anti-dilution protection (which would be triggered by a share or warrant issuance at less than $0.18945 price share or exercise price per share). As of June 30, 2017 and December 31, 2016, the fair value of the warrants was $0 and $34,838, respectively. The net change in fair value of $34,838 (gain) was recognized as change in fair value of option and warrant liabilities in the Company’s Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2017. The warrants expired on April 4, 2017.

The Company accounts for the liability warrants issued in accordance with ASC 815, “Derivatives and Hedging” as a freestanding liability instrument that is measured at fair value at each reporting date, based on its fair value, with changes in the fair values being recognized in the Company’s Condensed Consolidated Statements of Comprehensive Loss as a change in fair value of option/warrant liabilities.

In June 2015, the Company raised short-term working capital in the form of loans from shareholders of approximately $3 million with the loans carrying with it, options in RPC, equivalent to 15% of the current outstanding equity issued by RPC. RPC is a private company that is a majority shareholder of the Company. The RPC options were accounted for in accordance with ASC 718, “Compensation – Stock Compensation”. The fair value of the RPC options is estimated using the fair value of Akari Ordinary Shares times RPC’s ownership in Akari Ordinary Shares times 15% and was initially valued at approximately $26 million. These options do not relate to the share capital of Akari. The exact terms of these options have not been finalized. In September 2015, the Company recorded a liability to share options for $26 million, allocated $3 million as a loan discount and recorded interest expense over the estimated term of the loan amounting to $3 million recognized in the Condensed Consolidated Statements of Comprehensive Loss as a credit to the loan discount in 2015. The remaining $23 million was recorded as a non-cash financing expense in the Condensed Consolidated Statements of Comprehensive Loss during the quarter-ended September 30, 2015.

The fair value of the RPC options was $4,995,020 and $7,627,970 as of June 30, 2017 and December 31, 2016, respectively. The fair value of the RPC options for the six months ended June 30, 2017 decreased by $2,632,950 and the change which represents a gain was recognized as change in fair value of option/warrant liabilities in the Condensed Consolidated Statements of Comprehensive Loss. The Company accounts for the RPC options as a liability in accordance with ASC 815-40-25, “Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock” and ASC 815-40-15, “Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock.”

The Company’s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following instruments as of the following dates:

	June 30,		December 31,
	2017		2016
Warrants	$	-	$	34,838
RPC options		4,995,020		7,627,970
Liabilities related to stock options and warrants	$	4,995,020	$	7,662,808

Fair value measurements using significant unobservable inputs (Level 3):

	Fair value of
	liabilities related
	to stock options
	and warrants
Balance at December 31, 2016	$	7,662,808

Changes in values of liabilities related to options and warrants		(2,667,788)

Balance at June 30, 2017	$	4,995,020

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Shareholders' Equity

6 Months Ended

Jun. 30, 2017

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

NOTE 4 – Shareholders’ Equity

Share Capital – The Company has 5,000,000,000 Ordinary Shares of authorized capital and 1,177,693,393 Ordinary Shares outstanding at June 30, 2017 and 1,177,693,383 at December 31, 2016.

On June 26, 2017, previously issued Deferred B Shares and Deferred C Shares were converted into 10 Ordinary Shares.

Share option plan – In accordance with the Company’s 2014 Equity Incentive Plan (the “Plan”) the number of shares that may be issued upon exercise of options under the Plan, shall not exceed 141,142,420 Ordinary Shares. At June 30, 2017, 68,625,035 Ordinary Shares are available for future issuance under the Plan. The option plan is administered by the Company’s board of directors and grants are made pursuant thereto by the compensation committee. The per share exercise price for the shares to be issued pursuant to the exercise of an option shall be such price equal to the fair market value of the Company’s Ordinary Shares on the grant date and set forth in the individual option agreement. Options expire ten years after the grant date and typically vest over one to four years.

The following is a summary of the Company’s share option activity and related information for employees and directors for the period ended June 30, 2017:

							Weighted
							average
			Weighted		Weighted		remaining
			average		average		contractual		Aggregate
	Number		exercise		grant date		term		intrinsic
	of shares		price		fair value		(in years)		value

Options outstanding as of January 1, 2017		79,372,198	$	0.29				8.7	$	-
Changes during the period:
Granted		13,650,000	$	0.09	$	0.06
Forfeited		(20,504,813)	$	0.34	$	0.21
Options outstanding at June 30, 2017		72,517,385	$	0.24				8.4	$	-
Exercisable options at June 30, 2017		37,537,943	$	0.30				8.4	$	-

The following is a summary of the Company’s non-vested share options at June 30, 2017 and changes during the six months ended June 30, 2017:

			Weighted
			average
	Number		grant date
	of shares		fair value

Non-vested options at January 1, 2017		53,885,712	$	0.24
Options granted		13,650,000	$	0.06
Options vested		(12,051,457)	$	0.14
Non-vested options forfeited		(20,504,813)	$	0.21
Non-vested at June 30, 2017		34,979,442	$	0.26

The Company accounts for awards of equity instruments issued to employees and directors under the fair value method of accounting and recognize such amounts, upon vesting, in general administrative and research and development expenses within its Condensed Consolidated Statements of Comprehensive Loss. The Company measures compensation cost for all share-based awards at fair value on the date of grant and recognize compensation expense in its Condensed Consolidated Statements of Comprehensive Loss using the straight-line method over the service period over which it expects the awards to vest.

The Company estimates the fair value of all time-vested options as of the date of grant using the Black-Scholes option valuation model, which was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Option valuation models require the input of highly subjective assumptions, including the expected share price volatility, which is calculated based on the historical volatility of peer companies. The Company uses a risk-free interest rate, based on the U.S. Treasury instruments in effect at the time of the grant, for the period comparable to the expected term of the option. Given its limited history with share option grants and exercises, the Company uses the “simplified” method in estimating the expected term, the period of time that options granted are expected to be outstanding, for its grants.

The Company classifies its stock-based payments as either liability-classified awards or as equity-classified awards. The Company remeasures liability-classified awards to fair value at each balance sheet date until the award is settled. The Company measures equity-classified awards at their grant date fair value and do not subsequently remeasure them. The Company has classified its stock-based payments which are settled in common stock as equity-classified awards and share-based payments that are settled in cash as liability-classified awards. Compensation costs related to equity-classified awards generally are equal to the grant-date fair value of the award amortized over the vesting period of the award. The liability for liability-classified awards generally is equal to the fair value of the award as of the balance sheet date multiplied by the percentage vested at the time. The Company charges (or credits) the change in the liability amounts from one balance sheet date to another to compensation expense. Below are the assumptions used for the options granted during the six months ended June 30, 2017 and 2016:

	June 30, 2017			June 30, 2016
Expected dividend yield		0	%		0	%
Expected volatility		78.77%-79.89	%		74.18%-80.71	%
Risk-free interest		1.21%-2.02	%		1.03%-1.52	%
Expected life		5.5-6.25 years			5.5-6.25 years

The following is a summary of the Company’s share options granted separated into ranges of exercise price:

									Remaining
	Options		Weighted				Options		contractual
	outstanding		average		Weighted		exercisable		life (years		Weighted
Exercise	at		remaining		average		at		for		average
price	June		contractual		exercise		June		exercisable		exercise
(range) ($)	30, 2017		life (years)		price ($)		30, 2017		options)		price ($)
0.05-0.19		37,963,350		9.19		0.13		14,425,053		8.85		0.15
0.32		33,257,535		8.22		0.32		21,816,390		8.22		0.32
0.60-0.75		290,000		6.70		0.72		290,000		6.70		0.72
0.98-1.56		311,500		2.74		1.33		311,500		2.74		1.33
2.00		695,000		6.23		2.00		695,000		6.23		2.00
		72,517,385						37,537,943

During the six months ended June 30, 2017 and June 30, 2016, the Company recorded approximately $1,748,000 and $1,622,000, respectively, in stock-based compensation expenses for employees and directors. At June 30, 2017, there was approximately $4,036,000 of unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Company’s share option plans which the Company expects to recognize over 2.4 years.

Warrants to service providers and investors – The warrants outstanding as of June 30, 2017, classified as equity, were issued in connection with several private placements of the Company are as follows:

	Number of		Exercise
Grant date	warrants		Price		Expiration date
2012 warrants		724,363		$ 1.72 - $ 2.00	August 3, 2017-November 30, 2017
2013 warrants		399,160		$ 2.00	January 16, 2018-September 17, 2018
		1,123,523

During the six months ended June 30, 2017, 658,723 warrants to purchase company shares expired.

Related Party Transactions

6 Months Ended

Jun. 30, 2017

NOTE 5 – Related Party Transactions

Office Lease – A non-employee director of the Company is also the CEO of The Doctors Laboratory (“TDL”). The Company leases its UK office space from TDL and has incurred expenses of approximately $67,000 and $74,000 plus VAT during the six months ended June 30, 2017 and 2016, respectively.

Loss Per Share

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

NOTE 6 – Loss Per Share

Basic loss per Ordinary Share is computed by dividing net loss available to ordinary shareholders by the weighted-average number of Ordinary Shares outstanding during the period. Diluted loss per common share is computed by dividing net loss available to ordinary shareholders by the sum of (1) the weighted-average number of Ordinary Shares outstanding during the period, (2) the dilutive effect of the assumed exercise of share options using the treasury stock method, and (3) the dilutive effect of other potentially dilutive securities.

	Three Months Ended June 30,				Six Months Ended June 30,
Loss per share	2017		2016		2017		2016
Company posted		Net loss		Net loss		Net loss		Net loss
Basic weighted average shares outstanding		1,177,693,383		1,177,693,383		1,177,693,383		1,177,693,383
Dilutive effect of Ordinary Share equivalents		None		None		None		None
Dilutive weighted average shares outstanding		1,177,693,383		1,177,693,383		1,177,693,383		1,177,693,383
Loss per common share (basic and diluted)	$	0.00	$	0.01	$	0.01	$	0.01

For purposes of the diluted net loss per share calculation, share options and warrants are considered to be potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share was the same for the periods presented due to the Company’s net loss position.

The following table shows the number of share equivalents that were excluded from the computation of diluted loss per share for the respective periods because the effect would have been anti-dilutive:

	Six Months Ended		Six Months Ended
	June 30, 2017		June 30, 2016
Total share options		72,517,385		76,928,864
Total warrants-equity classified		1,123,523		1,782,246
Total warrants-liability classified		-		5,806,280
Total share options and warrants		73,640,908		84,517,390

Contingencies

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

NOTE 7 – Contingencies

On May 12, 2017, a putative securities class action captioned Derek Da Ponte v. Akari Therapeutics, PLC, Gur Roshwalb, and Dov Elefant (Case 1:17-cv-03577) was filed in the U.S. District Court for the Southern District of New York against the Company, the Company’s former Chief Executive Officer and the Company’s Chief Financial Officer. The plaintiff asserted claims alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based primarily on the Company’s press releases issued on April 27, 2017 and May 11, 2017 concerning a research report about the Company prepared by a research company and actions taken by the Company after the report was issued. The purported class covers the period from March 30, 2017 to May 11, 2017. The complaint seeks unspecified damages and costs and fees. On May 19, 2017, an almost identical class action complaint captioned Shamoon v. Akari Therapeutics, PLC, Gur Roshwalb, and Dov Elefant (Case 1:17-cv-03783) was filed in the same court. On July 11-12, 2017, candidates to be lead plaintiff filed motions to consolidate the cases and appoint a lead plaintiff. The court has scheduled a hearing on those motions for August 25, 2017. On August 10, 2017, the court issued a stipulated order: (i) consolidating the class actions under the caption In re: Akari Therapeutics, PLC Securities Litigation; (ii) ordering lead plaintiff to file and serve a consolidated amended complaint within 60 days after the appointment of lead plaintiff and lead plaintiff’s counsel; and (iii) ordering defendants to move, answer, otherwise respond to the consolidated amended complaint within 45 days of being served with it. The Company intends to vigorously defend itself against this lawsuit. At this time, the Company is unable to estimate the ultimate outcome of this legal matter and its impact on the Company.

Subsequent Events

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 8 – Subsequent Events

On July 14, 2017, the Company effectively increased its authorized share capital from 5,000,000,000 Ordinary Shares to 10,000,000,000 Ordinary Shares.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Consolidation, Policy [Policy Text Block]

All intercompany transactions have been eliminated.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Use of Estimates, Policy [Policy Text Block]

Fair Value Measurement, Policy [Policy Text Block]

Cash and Cash Equivalents, Policy [Policy Text Block]

Investment, Policy [Policy Text Block]

Short-term investments – Short-term investments consist of certificates of deposit that are expected to be converted into cash within one year.

Restricted deposit [Policy Text Block]

Restricted cash – Restricted cash is collateral for a letter of credit related to the Company’s office lease.

Prepaid Expenses and Other Current Assets [Policy Text Block]

Prepaid Expenses and Other Current Assets – Prepaid expenses and other current assets consist principally of VAT receivables and prepaid expenses.

Property, Plant and Equipment, Policy [Policy Text Block]

	Years

Computers, peripheral, and scientific equipment		3
Office furniture and equipment		3

Depreciation expense for the three and six months ended June 30, 2017 and 2016 was $10,952 and $9,418 and $21,044 and $17,257, respectively.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Accrued Expenses [Policy Text Block]

Research and Development Expense, Policy [Policy Text Block]

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Income Tax, Policy [Policy Text Block]

Income Tax Uncertainties, Policy [Policy Text Block]

Comprehensive Income, Policy [Policy Text Block]

Balance January 1, 2017	$	(280,097)

Net current period foreign currency translation loss		(93,730)

Balance June 30, 2017	$	(373,827)

New Accounting Pronouncements, Policy [Policy Text Block]

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2017

Significant Accounting Policies [Line Items]

Schedule of Rate of Depreciation of Property, Plant and Equipment [Table Text Block]

Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:

	Years

Computers, peripheral, and scientific equipment		3
Office furniture and equipment		3

Comprehensive Income (Loss) [Table Text Block]

Balance January 1, 2017	$	(280,097)

Net current period foreign currency translation loss		(93,730)

Balance June 30, 2017	$	(373,827)

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2017

Class of Stock [Line Items]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

	June 30, 2017				December 31, 2016				Fair
	Carrying		Fair		Carrying		Fair		Value
	Amount		Value		Amount		Value		Levels
Liability related to RPC options	$	4,995,020	$	4,995,020	$	7,627,970	$	7,627,970		3
Liability related to warrants		-		-		34,838		34,838		3
	$	4,995,020	$	4,995,020	$	7,662,808	$	7,662,808

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

Some of the issued warrants contain non-standard anti-dilution terms and accordingly are recorded as liabilities.

	June 30, 2017				December 31, 2016
	Carrying		Fair		Carrying		Fair		Fair
	Amount		Value		Amount		Value		Value
	$		$		$		$		Levels		Reference

Cash and cash equivalents		30,118,882		30,118,882		34,098,812		34,098,812		1		Note 2
Short-term investment		-		-		10,021,963		10,021,963		1		Note 2
Restricted cash		142,200		142,200		142,168		142,168		1		Note 2
Liability related to options and warrants		4,995,020		4,995,020		7,662,808		7,662,808		3		Note 4

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

The Company’s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following instruments as of the following dates:

	June 30,		December 31,
	2017		2016
Warrants	$	-	$	34,838
RPC options		4,995,020		7,627,970
Liabilities related to stock options and warrants	$	4,995,020	$	7,662,808

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Fair value measurements using significant unobservable inputs (Level 3):

	Fair value of
	liabilities related
	to stock options
	and warrants
Balance at December 31, 2016	$	7,662,808

Changes in values of liabilities related to options and warrants		(2,667,788)

Balance at June 30, 2017	$	4,995,020

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Shareholders' Equity (Tables)

6 Months Ended

Jun. 30, 2017

Stockholders' Equity Note [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following is a summary of the Company’s share option activity and related information for employees and directors for the period ended June 30, 2017:

							Weighted
							average
			Weighted		Weighted		remaining
			average		average		contractual		Aggregate
	Number		exercise		grant date		term		intrinsic
	of shares		price		fair value		(in years)		value

Options outstanding as of January 1, 2017		79,372,198	$	0.29				8.7	$	-
Changes during the period:
Granted		13,650,000	$	0.09	$	0.06
Forfeited		(20,504,813)	$	0.34	$	0.21
Options outstanding at June 30, 2017		72,517,385	$	0.24				8.4	$	-
Exercisable options at June 30, 2017		37,537,943	$	0.30				8.4	$	-

Schedule of Nonvested Share Activity [Table Text Block]

The following is a summary of the Company’s non-vested share options at June 30, 2017 and changes during the six months ended June 30, 2017:

			Weighted
			average
	Number		grant date
	of shares		fair value

Non-vested options at January 1, 2017		53,885,712	$	0.24
Options granted		13,650,000	$	0.06
Options vested		(12,051,457)	$	0.14
Non-vested options forfeited		(20,504,813)	$	0.21
Non-vested at June 30, 2017		34,979,442	$	0.26

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Below are the assumptions used for the options granted during the six months ended June 30, 2017 and 2016:

	June 30, 2017			June 30, 2016
Expected dividend yield		0	%		0	%
Expected volatility		78.77%-79.89	%		74.18%-80.71	%
Risk-free interest		1.21%-2.02	%		1.03%-1.52	%
Expected life		5.5-6.25 years			5.5-6.25 years

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

The following is a summary of the Company’s share options granted separated into ranges of exercise price:

									Remaining
	Options		Weighted				Options		contractual
	outstanding		average		Weighted		exercisable		life (years		Weighted
Exercise	at		remaining		average		at		for		average
price	June		contractual		exercise		June		exercisable		exercise
(range) ($)	30, 2017		life (years)		price ($)		30, 2017		options)		price ($)
0.05-0.19		37,963,350		9.19		0.13		14,425,053		8.85		0.15
0.32		33,257,535		8.22		0.32		21,816,390		8.22		0.32
0.60-0.75		290,000		6.70		0.72		290,000		6.70		0.72
0.98-1.56		311,500		2.74		1.33		311,500		2.74		1.33
2.00		695,000		6.23		2.00		695,000		6.23		2.00
		72,517,385						37,537,943

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

The warrants outstanding as of June 30, 2017, classified as equity, were issued in connection with several private placements of the Company are as follows:

	Number of		Exercise
Grant date	warrants		Price		Expiration date
2012 warrants		724,363		$ 1.72 - $ 2.00	August 3, 2017-November 30, 2017
2013 warrants		399,160		$ 2.00	January 16, 2018-September 17, 2018
		1,123,523

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
Loss per share	2017		2016		2017		2016
Company posted		Net loss		Net loss		Net loss		Net loss
Basic weighted average shares outstanding		1,177,693,383		1,177,693,383		1,177,693,383		1,177,693,383
Dilutive effect of Ordinary Share equivalents		None		None		None		None
Dilutive weighted average shares outstanding		1,177,693,383		1,177,693,383		1,177,693,383		1,177,693,383
Loss per common share (basic and diluted)	$	0.00	$	0.01	$	0.01	$	0.01

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Six Months Ended		Six Months Ended
	June 30, 2017		June 30, 2016
Total share options		72,517,385		76,928,864
Total warrants-equity classified		1,123,523		1,782,246
Total warrants-liability classified		-		5,806,280
Total share options and warrants		73,640,908		84,517,390

Summary of Significant Accounting Policies (Details)	6 Months Ended
Summary of Significant Accounting Policies (Details)	Jun. 30, 2017
Computers, peripheral, and scientific equipment [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office furniture and equipment [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Significant Accounting Policies [Line Items]
Beginning Balance			$ (280,097)
Net current period foreign currency translation loss	$ (48,577)	$ (155,409)	(93,730)	$ (348,353)
Ending Balance	$ (373,827)		$ (373,827)

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Significant Accounting Policies [Line Items]
Research and Development Expense	$ 3,782,185	$ 5,443,105	$ 9,784,884	$ 6,942,648
Depreciation	10,952	9,418	$ 21,044	17,257
Patents [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period			22 years
Amortization of Intangible Assets	$ 762	$ 773	$ 1,509	$ 1,528

Fair Value Measurements (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities Fair Value Disclosure	$ 4,995,020	$ 7,662,808
Liabilities	9,201,377	11,771,128
Fair Value, Inputs, Level 3 [Member] \| Liability related to RPC options [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities Fair Value Disclosure	4,995,020	7,627,970
Liabilities	4,995,020	7,627,970
Fair Value, Inputs, Level 3 [Member] \| Liability related to warrants [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities Fair Value Disclosure	0	34,838
Liabilities	$ 0	$ 34,838

Fair Value Measurements (Details 1) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 30,118,882	$ 34,098,812	$ 9,662,454	$ 68,919,995
Short-term investments	0	10,021,963
Restricted cash	142,200	142,168
Liability related to options and warrants	4,995,020	7,662,808
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investments	0	10,021,963
Cash and cash equivalents	30,118,882	34,098,812
Restricted cash	142,200	142,168
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liability related to options and warrants	$ 4,995,020	$ 7,662,808

Fair Value Measurements (Details 2) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	$ 4,995,020	$ 7,627,970
RPC Pharma Ltd [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	2,632,950
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	4,995,020	7,662,808
Fair Value, Inputs, Level 3 [Member] \| Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	0	34,838
Fair Value, Inputs, Level 3 [Member] \| RPC Pharma Ltd [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	$ 4,995,020	$ 7,627,970

Fair Value Measurements (Details 3) - USD ($)	3 Months Ended		6 Months Ended
Fair Value Measurements (Details 3) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Changes in values of liabilities related to options and warrants	$ (6,999,529)	$ (976,452)	$ (2,667,788)	$ (1,680,787)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Balance			4,995,020
Changes in values of liabilities related to options and warrants			(2,667,788)
Balance	$ 7,662,808		$ 7,662,808

Fair Value Measurements (Details Textual) - USD ($)	1 Months Ended		3 Months Ended	6 Months Ended
Fair Value Measurements (Details Textual) - USD ($)	Sep. 30, 2015	Jun. 30, 2015	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award				5,806,280
Warrant Issuance Exercise Price Description				share or warrant issuance at less than $0.18945 price share or exercise price per share
Liability Related To Stock Options and Warrants			$ 4,995,020	$ 4,995,020	$ 7,662,808
Stock Options And Warrants Fair Value Disclosure			4,995,020	4,995,020	7,627,970
Debt Instrument, Unamortized Discount	$ 3,000,000
Interest Expense, Other	3,000,000
Financing Interest Expense	23,000,000
Derivative Liability, Fair Value, Gross Liability			0	0	$ 34,838
Derivative, Gain (Loss) on Derivative, Net			34,838	34,838
RPC Pharma Ltd [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Percentage Of Shares Outstanding		15.00%
Liability Related To Stock Options and Warrants	$ 26,000,000
Stock Options And Warrants Fair Value Disclosure			$ 2,632,950	$ 2,632,950
Short-term Debt		$ 3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 26,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		15.00%

Shareholders' Equity (Details) - USD ($)	6 Months Ended	12 Months Ended
Shareholders' Equity (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Number of shares, Options outstanding at end of the period	72,517,385
Number of shares, Options exercisable at end of the period	37,537,943
Employee Stock Option [Member]
Class of Stock [Line Items]
Number of shares, Outstanding at beginning of the period	79,372,198
Number of shares, Granted	13,650,000
Number of shares, Forfeited	(20,504,813)
Number of shares, Options outstanding at end of the period	72,517,385	79,372,198
Number of shares, Options exercisable at end of the period	37,537,943
Weighted average exercise price, Outstanding at beginning of the period	$ 0.29
Weighted average exercise price, Granted	0.09
Weighted average exercise price, Forfeited	0.34
Weighted average exercise price,outstanding at end of the period	0.24	$ 0.29
Options exercisable at end of the period, Weighted average exercise price	0.3
Weighted average grant date fair value Granted	0.06
Weighted average grant date fair value Forfeited	$ 0.21
Weighted average remaining contractual term, Options outstanding during the period (in years)	8 years 4 months 24 days	8 years 8 months 12 days
Weighted average remaining contractual term, Options exercisable at end of the period (in years)	8 years 4 months 24 days
Aggregate intrinsic value, Options outstanding at beginning of the period	$ 0
Aggregate intrinsic value, Options outstanding at end of the period	0	$ 0
Aggregate intrinsic value, Options exercisable at end of the period	$ 0

Shareholders' Equity (Details 1)	6 Months Ended
Shareholders' Equity (Details 1)	Jun. 30, 2017 $ / shares shares
Employee Stock Option [Member]
Number of Shares
Non-vested options granted \| shares	13,650,000
Non-vested options Vested \| shares	(12,051,457)
Non-vested options forfeited \| shares	(20,504,813)
Weighted average grant date fair value
Non-vested options granted \| $ / shares	$ 0.06
Non-vested options Vested \| $ / shares	0.14
Non-vested options forfeited \| $ / shares	$ 0.21
Nonvested Option [Member]
Number of Shares
Non-vested options at January 1, 2017 \| shares	53,885,712
Non-vested at June 30, 2017 \| shares	34,979,442
Weighted average grant date fair value
Non-vested options at January 1, 2017 \| $ / shares	$ 0.24
Non-vested at June 30, 2017 \| $ / shares	$ 0.26

Shareholders' Equity (Details 2)	6 Months Ended
Shareholders' Equity (Details 2)	Jun. 30, 2017	Jun. 30, 2016
Class of Stock [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Class of Stock [Line Items]
Expected volatility	78.77%	74.18%
Risk-free interest	1.21%	1.03%
Expected life	5 years 6 months	5 years 6 months
Maximum [Member]
Class of Stock [Line Items]
Expected volatility	79.89%	80.71%
Risk-free interest	2.02%	1.52%
Expected life	6 years 3 months	6 years 3 months

Shareholders' Equity (Details 3)	6 Months Ended
Shareholders' Equity (Details 3)	Jun. 30, 2017 $ / shares shares
Class of Stock [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number \| shares	72,517,385
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number \| shares	37,537,943
Exercise Price Range One [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 0.05
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 0.19
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number \| shares	37,963,350
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years 2 months 8 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.13
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number \| shares	14,425,053
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	8 years 10 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.15
Exercise Price Range Two [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 0.32
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number \| shares	33,257,535
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	8 years 2 months 19 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.32
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number \| shares	21,816,390
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	8 years 2 months 19 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.32
Exercise Price Range Three [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	0.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 0.75
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number \| shares	290,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 8 months 12 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.72
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number \| shares	290,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 8 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.72
Exercise Price Range Four [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	0.98
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 1.56
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number \| shares	311,500
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	2 years 8 months 26 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 1.33
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number \| shares	311,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	2 years 8 months 26 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1.33
Exercise Price Range Five [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 2.00
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number \| shares	695,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 2 months 23 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 2.00
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number \| shares	695,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 2 months 23 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 2.00

Shareholders' Equity (Details 4)	6 Months Ended
Shareholders' Equity (Details 4)	Jun. 30, 2017 $ / shares shares
Class of Stock [Line Items]
Number of warrants \| shares	1,123,523
Warrants 2012 [Member]
Class of Stock [Line Items]
Number of warrants \| shares	724,363
Warrants 2012 [Member] \| Maximum [Member]
Class of Stock [Line Items]
Exercise Price \| $ / shares	$ 2.00
Expiration date	Nov. 30, 2017
Warrants 2012 [Member] \| Minimum [Member]
Class of Stock [Line Items]
Exercise Price \| $ / shares	$ 1.72
Expiration date	Aug. 03, 2017
Warrants 2013 [Member]
Class of Stock [Line Items]
Number of warrants \| shares	399,160
Exercise Price \| $ / shares	$ 2.00
Warrants 2013 [Member] \| Maximum [Member]
Class of Stock [Line Items]
Expiration date	Sep. 17, 2018
Warrants 2013 [Member] \| Minimum [Member]
Class of Stock [Line Items]
Expiration date	Jan. 16, 2018

Shareholders' Equity (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
Shareholders' Equity (Details Textual) - USD ($)	Jun. 26, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Class of Stock [Line Items]
Common Stock, Shares Authorized		5,000,000,000		5,000,000,000
Common Stock, Shares, Outstanding		1,177,693,393		1,177,693,383
Stock Issued During Period, Shares, Conversion of Convertible Securities	10
Non Employee [Member]
Class of Stock [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized		$ 4,036,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 4 months 24 days
Employees And Directors [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 1,748,000	$ 1,622,000
2014 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period		141,142,420
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		68,625,035
Warrant [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations		658,723

Related Party Transactions (Details Textual) - USD ($)	6 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
The Doctors Laboratory [Member]
Related Party Transaction [Line Items]
Operating Leases, Rent Expense	$ 67,000	$ 74,000

Loss Per Share (Details) - $ / shares	3 Months Ended		6 Months Ended
Loss Per Share (Details) - $ / shares	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Line Items]
Basic weighted average shares outstanding	1,177,693,383	1,177,693,383	1,177,693,383	1,177,693,383
Dilutive weighted average shares outstanding	1,177,693,383	1,177,693,383	1,177,693,383	1,177,693,383
Loss per common share (basic and diluted)	$ 0.00	$ 0.01	$ 0.01	$ 0.01

Loss Per Share (Details 1) - shares	6 Months Ended
Loss Per Share (Details 1) - shares	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Line Items]
Total stock options and warrants	73,640,908	84,517,390
Stock Options [Member]
Earnings Per Share [Line Items]
Total stock options and warrants	72,517,385	76,928,864
Warrants Equity Classified [Member]
Earnings Per Share [Line Items]
Total stock options and warrants	1,123,523	1,782,246
Warrants Liability Classified [Member]
Earnings Per Share [Line Items]
Total stock options and warrants	0	5,806,280

Subsequent Events (Details Textual) - shares	Jul. 14, 2017	Jul. 13, 2017	Jun. 30, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Common Stock, Shares Authorized			5,000,000,000	5,000,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Shares Authorized	10,000,000,000	5,000,000,000